Clinical Trial Update: Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma [Phase 4]

View source ↗

Summary

A Phase 4 trial investigating gut microbiome modulation to enhance checkpoint inhibitor efficacy in pancreatic cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Snippet

Sponsor: NYU Langone Health | Conditions: Pancreatic Cancer | Phase 4 | Status: WITHDRAWN